nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—Procainamide—Sunitinib—pancreatic cancer	0.311	1	CrCrCtD
Lidocaine—EGFR—pancreatic cancer	0.228	1	CbGaD
Lidocaine—EGFR—Erlotinib—pancreatic cancer	0.0729	0.203	CbGbCtD
Lidocaine—EGFR—Docetaxel—pancreatic cancer	0.0482	0.134	CbGbCtD
Lidocaine—CYP2A6—Tamoxifen—pancreatic cancer	0.0153	0.0425	CbGbCtD
Lidocaine—CYP2A6—Fluorouracil—pancreatic cancer	0.0113	0.0313	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0105	0.0291	CbGbCtD
Lidocaine—CYP3A7—Tamoxifen—pancreatic cancer	0.0105	0.0291	CbGbCtD
Lidocaine—CYP2B6—Tamoxifen—pancreatic cancer	0.00995	0.0277	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.00802	0.0223	CbGbCtD
Lidocaine—CYP3A7—Irinotecan—pancreatic cancer	0.00802	0.0223	CbGbCtD
Lidocaine—CYP3A5—Tamoxifen—pancreatic cancer	0.00784	0.0218	CbGbCtD
Lidocaine—CYP2B6—Irinotecan—pancreatic cancer	0.00764	0.0213	CbGbCtD
Lidocaine—CYP2C8—Tamoxifen—pancreatic cancer	0.00754	0.021	CbGbCtD
Lidocaine—CYP1A2—Dacarbazine—pancreatic cancer	0.00733	0.0204	CbGbCtD
Lidocaine—CYP3A5—Erlotinib—pancreatic cancer	0.00667	0.0185	CbGbCtD
Lidocaine—CYP2C8—Erlotinib—pancreatic cancer	0.00641	0.0178	CbGbCtD
Lidocaine—CYP3A5—Irinotecan—pancreatic cancer	0.00602	0.0167	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00588	0.0164	CbGbCtD
Lidocaine—CYP3A7—Docetaxel—pancreatic cancer	0.00588	0.0164	CbGbCtD
Lidocaine—CYP3A7—Sunitinib—pancreatic cancer	0.00585	0.0163	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00585	0.0163	CbGbCtD
Lidocaine—CYP1A2—Tamoxifen—pancreatic cancer	0.00583	0.0162	CbGbCtD
Lidocaine—CYP2C8—Fluorouracil—pancreatic cancer	0.00555	0.0155	CbGbCtD
Lidocaine—CYP2C9—Tamoxifen—pancreatic cancer	0.00526	0.0146	CbGbCtD
Lidocaine—ABCB1—Tamoxifen—pancreatic cancer	0.0051	0.0142	CbGbCtD
Lidocaine—CYP1A2—Erlotinib—pancreatic cancer	0.00496	0.0138	CbGbCtD
Lidocaine—CYP2D6—Tamoxifen—pancreatic cancer	0.00481	0.0134	CbGbCtD
Lidocaine—CYP3A5—Docetaxel—pancreatic cancer	0.00441	0.0123	CbGbCtD
Lidocaine—ABCB1—Gemcitabine—pancreatic cancer	0.0044	0.0122	CbGbCtD
Lidocaine—CYP3A5—Sunitinib—pancreatic cancer	0.00439	0.0122	CbGbCtD
Lidocaine—ABCB1—Erlotinib—pancreatic cancer	0.00434	0.0121	CbGbCtD
Lidocaine—CYP1A2—Fluorouracil—pancreatic cancer	0.0043	0.012	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—pancreatic cancer	0.00417	0.0116	CbGbCtD
Lidocaine—CYP2D6—Erlotinib—pancreatic cancer	0.00409	0.0114	CbGbCtD
Lidocaine—ABCB1—Irinotecan—pancreatic cancer	0.00392	0.0109	CbGbCtD
Lidocaine—CYP2C9—Fluorouracil—pancreatic cancer	0.00387	0.0108	CbGbCtD
Lidocaine—CYP3A4—Tamoxifen—pancreatic cancer	0.00306	0.0085	CbGbCtD
Lidocaine—ABCB1—Docetaxel—pancreatic cancer	0.00287	0.00799	CbGbCtD
Lidocaine—ABCB1—Sunitinib—pancreatic cancer	0.00286	0.00795	CbGbCtD
Lidocaine—CYP3A4—Erlotinib—pancreatic cancer	0.0026	0.00723	CbGbCtD
Lidocaine—CYP3A4—Irinotecan—pancreatic cancer	0.00235	0.00653	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—pancreatic cancer	0.00214	0.00595	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—pancreatic cancer	0.00202	0.00561	CbGbCtD
Lidocaine—CYP3A4—Docetaxel—pancreatic cancer	0.00172	0.00479	CbGbCtD
Lidocaine—CYP3A4—Sunitinib—pancreatic cancer	0.00171	0.00476	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—pancreatic cancer	0.00128	0.00357	CbGbCtD
Lidocaine—Back pain—Gemcitabine—pancreatic cancer	0.000116	0.0019	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—pancreatic cancer	0.000116	0.0019	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—pancreatic cancer	0.000114	0.00186	CcSEcCtD
Lidocaine—Urticaria—Tamoxifen—pancreatic cancer	0.000113	0.00185	CcSEcCtD
Lidocaine—Vision blurred—Fluorouracil—pancreatic cancer	0.000111	0.00182	CcSEcCtD
Lidocaine—Coma—Doxorubicin—pancreatic cancer	0.000111	0.00181	CcSEcCtD
Lidocaine—Paraesthesia—Sunitinib—pancreatic cancer	0.00011	0.00179	CcSEcCtD
Lidocaine—Dyspnoea—Sunitinib—pancreatic cancer	0.000109	0.00178	CcSEcCtD
Lidocaine—Loss of consciousness—Irinotecan—pancreatic cancer	0.000108	0.00177	CcSEcCtD
Lidocaine—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.000107	0.00174	CcSEcCtD
Lidocaine—Hypertension—Irinotecan—pancreatic cancer	0.000106	0.00174	CcSEcCtD
Lidocaine—Stomatitis—Docetaxel—pancreatic cancer	0.000106	0.00173	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000105	0.00172	CcSEcCtD
Lidocaine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000105	0.00171	CcSEcCtD
Lidocaine—Pain—Sunitinib—pancreatic cancer	0.000104	0.0017	CcSEcCtD
Lidocaine—Hypertension—Gemcitabine—pancreatic cancer	0.000104	0.00169	CcSEcCtD
Lidocaine—Asthenia—Tamoxifen—pancreatic cancer	0.000102	0.00167	CcSEcCtD
Lidocaine—Convulsion—Fluorouracil—pancreatic cancer	0.000102	0.00167	CcSEcCtD
Lidocaine—Chest pain—Gemcitabine—pancreatic cancer	0.000102	0.00167	CcSEcCtD
Lidocaine—Confusional state—Irinotecan—pancreatic cancer	0.000101	0.00166	CcSEcCtD
Lidocaine—Asthenia—Erlotinib—pancreatic cancer	0.000101	0.00165	CcSEcCtD
Lidocaine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000101	0.00164	CcSEcCtD
Lidocaine—Oedema—Irinotecan—pancreatic cancer	0.000101	0.00164	CcSEcCtD
Lidocaine—Chest pain—Fluorouracil—pancreatic cancer	0.000101	0.00164	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—pancreatic cancer	9.99e-05	0.00163	CcSEcCtD
Lidocaine—Shock—Irinotecan—pancreatic cancer	9.9e-05	0.00162	CcSEcCtD
Lidocaine—Nervous system disorder—Irinotecan—pancreatic cancer	9.87e-05	0.00161	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	9.86e-05	0.00161	CcSEcCtD
Lidocaine—Haemoglobin—Docetaxel—pancreatic cancer	9.84e-05	0.00161	CcSEcCtD
Lidocaine—Rhinitis—Docetaxel—pancreatic cancer	9.82e-05	0.0016	CcSEcCtD
Lidocaine—Oedema—Gemcitabine—pancreatic cancer	9.8e-05	0.0016	CcSEcCtD
Lidocaine—Anaphylactic shock—Gemcitabine—pancreatic cancer	9.8e-05	0.0016	CcSEcCtD
Lidocaine—Haemorrhage—Docetaxel—pancreatic cancer	9.79e-05	0.0016	CcSEcCtD
Lidocaine—Hypoaesthesia—Docetaxel—pancreatic cancer	9.74e-05	0.00159	CcSEcCtD
Lidocaine—Hyperhidrosis—Irinotecan—pancreatic cancer	9.73e-05	0.00159	CcSEcCtD
Lidocaine—Confusional state—Fluorouracil—pancreatic cancer	9.72e-05	0.00159	CcSEcCtD
Lidocaine—Oedema—Fluorouracil—pancreatic cancer	9.64e-05	0.00157	CcSEcCtD
Lidocaine—Anaphylactic shock—Fluorouracil—pancreatic cancer	9.64e-05	0.00157	CcSEcCtD
Lidocaine—Nervous system disorder—Gemcitabine—pancreatic cancer	9.61e-05	0.00157	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—pancreatic cancer	9.55e-05	0.00156	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—pancreatic cancer	9.55e-05	0.00156	CcSEcCtD
Lidocaine—Hyperhidrosis—Gemcitabine—pancreatic cancer	9.48e-05	0.00155	CcSEcCtD
Lidocaine—Nervous system disorder—Fluorouracil—pancreatic cancer	9.45e-05	0.00154	CcSEcCtD
Lidocaine—Visual impairment—Docetaxel—pancreatic cancer	9.44e-05	0.00154	CcSEcCtD
Lidocaine—Dizziness—Tamoxifen—pancreatic cancer	9.43e-05	0.00154	CcSEcCtD
Lidocaine—Hypotension—Irinotecan—pancreatic cancer	9.4e-05	0.00153	CcSEcCtD
Lidocaine—Dizziness—Erlotinib—pancreatic cancer	9.33e-05	0.00152	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—pancreatic cancer	9.24e-05	0.00151	CcSEcCtD
Lidocaine—Hypotension—Gemcitabine—pancreatic cancer	9.16e-05	0.00149	CcSEcCtD
Lidocaine—Eye disorder—Docetaxel—pancreatic cancer	9.15e-05	0.00149	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	9.13e-05	0.00149	CcSEcCtD
Lidocaine—Cardiac disorder—Docetaxel—pancreatic cancer	9.09e-05	0.00148	CcSEcCtD
Lidocaine—Flushing—Docetaxel—pancreatic cancer	9.09e-05	0.00148	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—pancreatic cancer	9.08e-05	0.00148	CcSEcCtD
Lidocaine—Vomiting—Tamoxifen—pancreatic cancer	9.07e-05	0.00148	CcSEcCtD
Lidocaine—Paraesthesia—Irinotecan—pancreatic cancer	9.04e-05	0.00147	CcSEcCtD
Lidocaine—Hypotension—Fluorouracil—pancreatic cancer	9.01e-05	0.00147	CcSEcCtD
Lidocaine—Hypersensitivity—Sunitinib—pancreatic cancer	9e-05	0.00147	CcSEcCtD
Lidocaine—Rash—Tamoxifen—pancreatic cancer	8.99e-05	0.00147	CcSEcCtD
Lidocaine—Dermatitis—Tamoxifen—pancreatic cancer	8.99e-05	0.00147	CcSEcCtD
Lidocaine—Vomiting—Erlotinib—pancreatic cancer	8.97e-05	0.00146	CcSEcCtD
Lidocaine—Dyspnoea—Irinotecan—pancreatic cancer	8.97e-05	0.00146	CcSEcCtD
Lidocaine—Somnolence—Irinotecan—pancreatic cancer	8.95e-05	0.00146	CcSEcCtD
Lidocaine—Headache—Tamoxifen—pancreatic cancer	8.94e-05	0.00146	CcSEcCtD
Lidocaine—Rash—Erlotinib—pancreatic cancer	8.9e-05	0.00145	CcSEcCtD
Lidocaine—Dermatitis—Erlotinib—pancreatic cancer	8.89e-05	0.00145	CcSEcCtD
Lidocaine—Angiopathy—Docetaxel—pancreatic cancer	8.88e-05	0.00145	CcSEcCtD
Lidocaine—Immune system disorder—Docetaxel—pancreatic cancer	8.84e-05	0.00144	CcSEcCtD
Lidocaine—Headache—Erlotinib—pancreatic cancer	8.84e-05	0.00144	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—pancreatic cancer	8.83e-05	0.00144	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—pancreatic cancer	8.83e-05	0.00144	CcSEcCtD
Lidocaine—Paraesthesia—Gemcitabine—pancreatic cancer	8.8e-05	0.00144	CcSEcCtD
Lidocaine—Chills—Docetaxel—pancreatic cancer	8.79e-05	0.00143	CcSEcCtD
Lidocaine—Asthenia—Sunitinib—pancreatic cancer	8.77e-05	0.00143	CcSEcCtD
Lidocaine—Dyspnoea—Gemcitabine—pancreatic cancer	8.74e-05	0.00143	CcSEcCtD
Lidocaine—Somnolence—Gemcitabine—pancreatic cancer	8.72e-05	0.00142	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	8.69e-05	0.00142	CcSEcCtD
Lidocaine—Paraesthesia—Fluorouracil—pancreatic cancer	8.66e-05	0.00141	CcSEcCtD
Lidocaine—Pain—Irinotecan—pancreatic cancer	8.61e-05	0.0014	CcSEcCtD
Lidocaine—Dyspnoea—Fluorouracil—pancreatic cancer	8.59e-05	0.0014	CcSEcCtD
Lidocaine—Somnolence—Fluorouracil—pancreatic cancer	8.57e-05	0.0014	CcSEcCtD
Lidocaine—Erythema—Docetaxel—pancreatic cancer	8.52e-05	0.00139	CcSEcCtD
Lidocaine—Nausea—Tamoxifen—pancreatic cancer	8.47e-05	0.00138	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	8.46e-05	0.00138	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—pancreatic cancer	8.4e-05	0.00137	CcSEcCtD
Lidocaine—Pain—Gemcitabine—pancreatic cancer	8.38e-05	0.00137	CcSEcCtD
Lidocaine—Nausea—Erlotinib—pancreatic cancer	8.38e-05	0.00137	CcSEcCtD
Lidocaine—Dysgeusia—Docetaxel—pancreatic cancer	8.35e-05	0.00136	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	8.32e-05	0.00136	CcSEcCtD
Lidocaine—Feeling abnormal—Irinotecan—pancreatic cancer	8.29e-05	0.00135	CcSEcCtD
Lidocaine—Asthma—Epirubicin—pancreatic cancer	8.25e-05	0.00135	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—pancreatic cancer	8.25e-05	0.00135	CcSEcCtD
Lidocaine—Back pain—Docetaxel—pancreatic cancer	8.25e-05	0.00135	CcSEcCtD
Lidocaine—Pain—Fluorouracil—pancreatic cancer	8.24e-05	0.00134	CcSEcCtD
Lidocaine—Dizziness—Sunitinib—pancreatic cancer	8.08e-05	0.00132	CcSEcCtD
Lidocaine—Feeling abnormal—Gemcitabine—pancreatic cancer	8.08e-05	0.00132	CcSEcCtD
Lidocaine—Feeling abnormal—Fluorouracil—pancreatic cancer	7.94e-05	0.0013	CcSEcCtD
Lidocaine—Vomiting—Sunitinib—pancreatic cancer	7.77e-05	0.00127	CcSEcCtD
Lidocaine—Rash—Sunitinib—pancreatic cancer	7.7e-05	0.00126	CcSEcCtD
Lidocaine—Dermatitis—Sunitinib—pancreatic cancer	7.7e-05	0.00126	CcSEcCtD
Lidocaine—Urticaria—Fluorouracil—pancreatic cancer	7.66e-05	0.00125	CcSEcCtD
Lidocaine—Headache—Sunitinib—pancreatic cancer	7.65e-05	0.00125	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—pancreatic cancer	7.64e-05	0.00125	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—pancreatic cancer	7.64e-05	0.00125	CcSEcCtD
Lidocaine—Loss of consciousness—Docetaxel—pancreatic cancer	7.49e-05	0.00122	CcSEcCtD
Lidocaine—Hypersensitivity—Irinotecan—pancreatic cancer	7.41e-05	0.00121	CcSEcCtD
Lidocaine—Convulsion—Docetaxel—pancreatic cancer	7.39e-05	0.00121	CcSEcCtD
Lidocaine—Hypertension—Docetaxel—pancreatic cancer	7.36e-05	0.0012	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—pancreatic cancer	7.36e-05	0.0012	CcSEcCtD
Lidocaine—Chest pain—Docetaxel—pancreatic cancer	7.26e-05	0.00118	CcSEcCtD
Lidocaine—Nausea—Sunitinib—pancreatic cancer	7.26e-05	0.00118	CcSEcCtD
Lidocaine—Asthenia—Irinotecan—pancreatic cancer	7.22e-05	0.00118	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—pancreatic cancer	7.21e-05	0.00118	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—pancreatic cancer	7.17e-05	0.00117	CcSEcCtD
Lidocaine—Hypersensitivity—Fluorouracil—pancreatic cancer	7.1e-05	0.00116	CcSEcCtD
Lidocaine—Asthenia—Gemcitabine—pancreatic cancer	7.03e-05	0.00115	CcSEcCtD
Lidocaine—Confusional state—Docetaxel—pancreatic cancer	7.01e-05	0.00114	CcSEcCtD
Lidocaine—Oedema—Docetaxel—pancreatic cancer	6.96e-05	0.00114	CcSEcCtD
Lidocaine—Anaphylactic shock—Docetaxel—pancreatic cancer	6.96e-05	0.00114	CcSEcCtD
Lidocaine—Shock—Docetaxel—pancreatic cancer	6.84e-05	0.00112	CcSEcCtD
Lidocaine—Nervous system disorder—Docetaxel—pancreatic cancer	6.82e-05	0.00111	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—pancreatic cancer	6.81e-05	0.00111	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—pancreatic cancer	6.72e-05	0.0011	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.67e-05	0.00109	CcSEcCtD
Lidocaine—Dizziness—Irinotecan—pancreatic cancer	6.66e-05	0.00109	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—pancreatic cancer	6.64e-05	0.00108	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—pancreatic cancer	6.64e-05	0.00108	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—pancreatic cancer	6.62e-05	0.00108	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—pancreatic cancer	6.6e-05	0.00108	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—pancreatic cancer	6.57e-05	0.00107	CcSEcCtD
Lidocaine—Hypotension—Docetaxel—pancreatic cancer	6.5e-05	0.00106	CcSEcCtD
Lidocaine—Vomiting—Irinotecan—pancreatic cancer	6.4e-05	0.00104	CcSEcCtD
Lidocaine—Dizziness—Fluorouracil—pancreatic cancer	6.37e-05	0.00104	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—pancreatic cancer	6.37e-05	0.00104	CcSEcCtD
Lidocaine—Rash—Irinotecan—pancreatic cancer	6.35e-05	0.00104	CcSEcCtD
Lidocaine—Dermatitis—Irinotecan—pancreatic cancer	6.34e-05	0.00103	CcSEcCtD
Lidocaine—Headache—Irinotecan—pancreatic cancer	6.3e-05	0.00103	CcSEcCtD
Lidocaine—Paraesthesia—Docetaxel—pancreatic cancer	6.25e-05	0.00102	CcSEcCtD
Lidocaine—Vomiting—Gemcitabine—pancreatic cancer	6.23e-05	0.00102	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—pancreatic cancer	6.22e-05	0.00102	CcSEcCtD
Lidocaine—Dyspnoea—Docetaxel—pancreatic cancer	6.2e-05	0.00101	CcSEcCtD
Lidocaine—Somnolence—Docetaxel—pancreatic cancer	6.18e-05	0.00101	CcSEcCtD
Lidocaine—Rash—Gemcitabine—pancreatic cancer	6.18e-05	0.00101	CcSEcCtD
Lidocaine—Dermatitis—Gemcitabine—pancreatic cancer	6.18e-05	0.00101	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—pancreatic cancer	6.17e-05	0.00101	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—pancreatic cancer	6.16e-05	0.001	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—pancreatic cancer	6.14e-05	0.001	CcSEcCtD
Lidocaine—Headache—Gemcitabine—pancreatic cancer	6.14e-05	0.001	CcSEcCtD
Lidocaine—Flushing—Epirubicin—pancreatic cancer	6.13e-05	0.001	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—pancreatic cancer	6.13e-05	0.001	CcSEcCtD
Lidocaine—Vomiting—Fluorouracil—pancreatic cancer	6.13e-05	0.001	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—pancreatic cancer	6.13e-05	0.001	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—pancreatic cancer	6.11e-05	0.000997	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.08e-05	0.000992	CcSEcCtD
Lidocaine—Rash—Fluorouracil—pancreatic cancer	6.08e-05	0.000992	CcSEcCtD
Lidocaine—Dermatitis—Fluorouracil—pancreatic cancer	6.07e-05	0.000991	CcSEcCtD
Lidocaine—Headache—Fluorouracil—pancreatic cancer	6.04e-05	0.000985	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.01e-05	0.00098	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—pancreatic cancer	5.99e-05	0.000978	CcSEcCtD
Lidocaine—Nausea—Irinotecan—pancreatic cancer	5.98e-05	0.000975	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—pancreatic cancer	5.97e-05	0.000973	CcSEcCtD
Lidocaine—Pain—Docetaxel—pancreatic cancer	5.95e-05	0.000971	CcSEcCtD
Lidocaine—Chills—Epirubicin—pancreatic cancer	5.93e-05	0.000967	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—pancreatic cancer	5.89e-05	0.000961	CcSEcCtD
Lidocaine—Nausea—Gemcitabine—pancreatic cancer	5.82e-05	0.00095	CcSEcCtD
Lidocaine—Erythema—Epirubicin—pancreatic cancer	5.75e-05	0.000938	CcSEcCtD
Lidocaine—Feeling abnormal—Docetaxel—pancreatic cancer	5.73e-05	0.000935	CcSEcCtD
Lidocaine—Nausea—Fluorouracil—pancreatic cancer	5.73e-05	0.000934	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—pancreatic cancer	5.71e-05	0.000932	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—pancreatic cancer	5.7e-05	0.00093	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—pancreatic cancer	5.67e-05	0.000925	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—pancreatic cancer	5.67e-05	0.000925	CcSEcCtD
Lidocaine—Tension—Epirubicin—pancreatic cancer	5.64e-05	0.000921	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—pancreatic cancer	5.63e-05	0.000919	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—pancreatic cancer	5.58e-05	0.000911	CcSEcCtD
Lidocaine—Back pain—Epirubicin—pancreatic cancer	5.56e-05	0.000907	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—pancreatic cancer	5.54e-05	0.000905	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—pancreatic cancer	5.52e-05	0.000901	CcSEcCtD
Lidocaine—Chills—Doxorubicin—pancreatic cancer	5.48e-05	0.000895	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—pancreatic cancer	5.42e-05	0.000884	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—pancreatic cancer	5.32e-05	0.000868	CcSEcCtD
Lidocaine—Agitation—Epirubicin—pancreatic cancer	5.28e-05	0.000862	CcSEcCtD
Lidocaine—Tension—Doxorubicin—pancreatic cancer	5.22e-05	0.000852	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—pancreatic cancer	5.21e-05	0.00085	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—pancreatic cancer	5.17e-05	0.000843	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—pancreatic cancer	5.15e-05	0.00084	CcSEcCtD
Lidocaine—Hypersensitivity—Docetaxel—pancreatic cancer	5.13e-05	0.000836	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—pancreatic cancer	5.05e-05	0.000825	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—pancreatic cancer	5.01e-05	0.000818	CcSEcCtD
Lidocaine—Asthenia—Docetaxel—pancreatic cancer	4.99e-05	0.000814	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—pancreatic cancer	4.98e-05	0.000813	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—pancreatic cancer	4.96e-05	0.00081	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—pancreatic cancer	4.9e-05	0.000799	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—pancreatic cancer	4.89e-05	0.000798	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—pancreatic cancer	4.88e-05	0.000796	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—pancreatic cancer	4.73e-05	0.000772	CcSEcCtD
Lidocaine—Oedema—Epirubicin—pancreatic cancer	4.69e-05	0.000766	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—pancreatic cancer	4.69e-05	0.000766	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—pancreatic cancer	4.68e-05	0.000763	CcSEcCtD
Lidocaine—Shock—Epirubicin—pancreatic cancer	4.62e-05	0.000753	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—pancreatic cancer	4.61e-05	0.000752	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—pancreatic cancer	4.6e-05	0.000751	CcSEcCtD
Lidocaine—Dizziness—Docetaxel—pancreatic cancer	4.6e-05	0.000751	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—pancreatic cancer	4.59e-05	0.000749	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—pancreatic cancer	4.54e-05	0.00074	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—pancreatic cancer	4.53e-05	0.000739	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—pancreatic cancer	4.51e-05	0.000736	CcSEcCtD
Lidocaine—Vomiting—Docetaxel—pancreatic cancer	4.42e-05	0.000722	CcSEcCtD
Lidocaine—Rash—Docetaxel—pancreatic cancer	4.39e-05	0.000716	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—pancreatic cancer	4.38e-05	0.000715	CcSEcCtD
Lidocaine—Dermatitis—Docetaxel—pancreatic cancer	4.38e-05	0.000715	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—pancreatic cancer	4.38e-05	0.000714	CcSEcCtD
Lidocaine—Headache—Docetaxel—pancreatic cancer	4.36e-05	0.000711	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.34e-05	0.000708	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—pancreatic cancer	4.34e-05	0.000708	CcSEcCtD
Lidocaine—Shock—Doxorubicin—pancreatic cancer	4.27e-05	0.000697	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—pancreatic cancer	4.26e-05	0.000695	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—pancreatic cancer	4.21e-05	0.000687	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.2e-05	0.000685	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—pancreatic cancer	4.18e-05	0.000683	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—pancreatic cancer	4.17e-05	0.000681	CcSEcCtD
Lidocaine—Nausea—Docetaxel—pancreatic cancer	4.13e-05	0.000674	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—pancreatic cancer	4.06e-05	0.000662	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.05e-05	0.000661	CcSEcCtD
Lidocaine—Pain—Epirubicin—pancreatic cancer	4.01e-05	0.000655	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—pancreatic cancer	3.9e-05	0.000636	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—pancreatic cancer	3.87e-05	0.000632	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—pancreatic cancer	3.87e-05	0.000631	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—pancreatic cancer	3.86e-05	0.00063	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.75e-05	0.000612	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—pancreatic cancer	3.73e-05	0.000608	CcSEcCtD
Lidocaine—Pain—Doxorubicin—pancreatic cancer	3.71e-05	0.000606	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—pancreatic cancer	3.58e-05	0.000584	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—pancreatic cancer	3.46e-05	0.000564	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—pancreatic cancer	3.45e-05	0.000563	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—pancreatic cancer	3.37e-05	0.000549	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—pancreatic cancer	3.2e-05	0.000522	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—pancreatic cancer	3.12e-05	0.000508	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—pancreatic cancer	3.1e-05	0.000506	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—pancreatic cancer	2.98e-05	0.000487	CcSEcCtD
Lidocaine—Rash—Epirubicin—pancreatic cancer	2.96e-05	0.000483	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—pancreatic cancer	2.96e-05	0.000482	CcSEcCtD
Lidocaine—Headache—Epirubicin—pancreatic cancer	2.94e-05	0.00048	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—pancreatic cancer	2.87e-05	0.000468	CcSEcCtD
Lidocaine—Nausea—Epirubicin—pancreatic cancer	2.79e-05	0.000455	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—pancreatic cancer	2.76e-05	0.00045	CcSEcCtD
Lidocaine—Rash—Doxorubicin—pancreatic cancer	2.74e-05	0.000447	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—pancreatic cancer	2.74e-05	0.000446	CcSEcCtD
Lidocaine—Headache—Doxorubicin—pancreatic cancer	2.72e-05	0.000444	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—pancreatic cancer	2.58e-05	0.000421	CcSEcCtD
Lidocaine—CYP3A7—Metabolism—TYMS—pancreatic cancer	5.21e-06	0.00013	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—NRAS—pancreatic cancer	5.2e-06	0.00013	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.18e-06	0.000129	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CD—pancreatic cancer	5.14e-06	0.000128	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PRSS1—pancreatic cancer	5.11e-06	0.000127	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GLP1R—pancreatic cancer	5.07e-06	0.000126	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	5.06e-06	0.000126	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CD—pancreatic cancer	5.05e-06	0.000126	CbGpPWpGaD
Lidocaine—EGFR—Disease—NOTCH1—pancreatic cancer	5.04e-06	0.000126	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMP—pancreatic cancer	5.02e-06	0.000125	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—DPYD—pancreatic cancer	4.98e-06	0.000124	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CD44—pancreatic cancer	4.96e-06	0.000124	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDH1—pancreatic cancer	4.91e-06	0.000123	CbGpPWpGaD
Lidocaine—EGFR—Disease—EGF—pancreatic cancer	4.87e-06	0.000122	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CD44—pancreatic cancer	4.85e-06	0.000121	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.84e-06	0.000121	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SMAD4—pancreatic cancer	4.79e-06	0.00012	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GLP1R—pancreatic cancer	4.77e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—TYMS—pancreatic cancer	4.77e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GCG—pancreatic cancer	4.76e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GLP1R—pancreatic cancer	4.73e-06	0.000118	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC2A2—pancreatic cancer	4.73e-06	0.000118	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.72e-06	0.000118	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—DPYD—pancreatic cancer	4.7e-06	0.000117	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CD—pancreatic cancer	4.69e-06	0.000117	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HES1—pancreatic cancer	4.68e-06	0.000117	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KRAS—pancreatic cancer	4.66e-06	0.000116	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—DPYD—pancreatic cancer	4.66e-06	0.000116	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GCG—pancreatic cancer	4.65e-06	0.000116	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—HRAS—pancreatic cancer	4.49e-06	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CB—pancreatic cancer	4.48e-06	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—pancreatic cancer	4.48e-06	0.000112	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—STK11—pancreatic cancer	4.48e-06	0.000112	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	4.46e-06	0.000111	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ARG2—pancreatic cancer	4.43e-06	0.000111	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	4.42e-06	0.00011	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CB—pancreatic cancer	4.4e-06	0.00011	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—STK11—pancreatic cancer	4.37e-06	0.000109	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.37e-06	0.000109	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—pancreatic cancer	4.36e-06	0.000109	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CD—pancreatic cancer	4.33e-06	0.000108	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL8—pancreatic cancer	4.3e-06	0.000107	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—PIK3CA—pancreatic cancer	4.28e-06	0.000107	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	4.28e-06	0.000107	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—APOE—pancreatic cancer	4.23e-06	0.000106	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.22e-06	0.000105	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CD44—pancreatic cancer	4.2e-06	0.000105	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.14e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.12e-06	0.000103	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PIK3CA—pancreatic cancer	4.11e-06	0.000103	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—pancreatic cancer	4.1e-06	0.000102	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CB—pancreatic cancer	4.09e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.08e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	4.04e-06	0.000101	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GCG—pancreatic cancer	4.03e-06	0.000101	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—DPYD—pancreatic cancer	3.98e-06	9.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—pancreatic cancer	3.96e-06	9.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—AKT1—pancreatic cancer	3.96e-06	9.88e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HIF1A—pancreatic cancer	3.92e-06	9.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TSC2—pancreatic cancer	3.91e-06	9.75e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOE—pancreatic cancer	3.88e-06	9.68e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMP—pancreatic cancer	3.87e-06	9.66e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TYMS—pancreatic cancer	3.85e-06	9.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.84e-06	9.59e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOE—pancreatic cancer	3.83e-06	9.55e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	3.82e-06	9.53e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—pancreatic cancer	3.81e-06	9.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—pancreatic cancer	3.8e-06	9.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—STK11—pancreatic cancer	3.79e-06	9.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CB—pancreatic cancer	3.78e-06	9.43e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	3.77e-06	9.42e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TYMS—pancreatic cancer	3.76e-06	9.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KDR—pancreatic cancer	3.75e-06	9.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—pancreatic cancer	3.74e-06	9.34e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.74e-06	9.32e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—pancreatic cancer	3.69e-06	9.2e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CD44—pancreatic cancer	3.66e-06	9.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CTNNB1—pancreatic cancer	3.63e-06	9.05e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.61e-06	9e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NFKBIA—pancreatic cancer	3.56e-06	8.89e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.56e-06	8.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—pancreatic cancer	3.54e-06	8.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOTCH1—pancreatic cancer	3.53e-06	8.81e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GCG—pancreatic cancer	3.51e-06	8.76e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	3.5e-06	8.74e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—pancreatic cancer	3.5e-06	8.73e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—pancreatic cancer	3.45e-06	8.61e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—NRAS—pancreatic cancer	3.45e-06	8.61e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CD44—pancreatic cancer	3.45e-06	8.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CD44—pancreatic cancer	3.42e-06	8.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—EGF—pancreatic cancer	3.41e-06	8.52e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—pancreatic cancer	3.38e-06	8.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—pancreatic cancer	3.36e-06	8.38e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	3.36e-06	8.38e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.35e-06	8.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CTNNB1—pancreatic cancer	3.35e-06	8.36e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.32e-06	8.28e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GCG—pancreatic cancer	3.31e-06	8.25e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—STK11—pancreatic cancer	3.3e-06	8.24e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.28e-06	8.19e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GCG—pancreatic cancer	3.28e-06	8.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—SRC—pancreatic cancer	3.28e-06	8.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—pancreatic cancer	3.26e-06	8.15e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TYMS—pancreatic cancer	3.26e-06	8.13e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—pancreatic cancer	3.16e-06	7.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRAS—pancreatic cancer	3.15e-06	7.87e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOE—pancreatic cancer	3.13e-06	7.81e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	3.12e-06	7.79e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—STK11—pancreatic cancer	3.11e-06	7.76e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—STK11—pancreatic cancer	3.08e-06	7.69e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	3.08e-06	7.68e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—DPYD—pancreatic cancer	3.07e-06	7.66e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOE—pancreatic cancer	3.06e-06	7.64e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CD—pancreatic cancer	3.04e-06	7.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—SRC—pancreatic cancer	3.03e-06	7.55e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	2.97e-06	7.41e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	2.93e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CD44—pancreatic cancer	2.92e-06	7.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—pancreatic cancer	2.92e-06	7.28e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.91e-06	7.27e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRAS—pancreatic cancer	2.91e-06	7.27e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—pancreatic cancer	2.9e-06	7.24e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.89e-06	7.22e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.86e-06	7.14e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TYMS—pancreatic cancer	2.84e-06	7.08e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.84e-06	7.08e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	2.83e-06	7.05e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GCG—pancreatic cancer	2.8e-06	6.99e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	2.76e-06	6.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	2.73e-06	6.81e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—pancreatic cancer	2.73e-06	6.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—pancreatic cancer	2.72e-06	6.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—pancreatic cancer	2.71e-06	6.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—TGFB1—pancreatic cancer	2.71e-06	6.75e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—pancreatic cancer	2.68e-06	6.7e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	2.68e-06	6.7e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TYMS—pancreatic cancer	2.68e-06	6.68e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—pancreatic cancer	2.67e-06	6.65e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—pancreatic cancer	2.66e-06	6.63e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TYMS—pancreatic cancer	2.65e-06	6.62e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOE—pancreatic cancer	2.65e-06	6.61e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	2.65e-06	6.6e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—STK11—pancreatic cancer	2.64e-06	6.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	2.54e-06	6.34e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—pancreatic cancer	2.53e-06	6.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	2.53e-06	6.3e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.51e-06	6.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—pancreatic cancer	2.51e-06	6.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—pancreatic cancer	2.49e-06	6.22e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	2.48e-06	6.2e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.47e-06	6.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—pancreatic cancer	2.43e-06	6.07e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	2.43e-06	6.06e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	2.39e-06	5.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—pancreatic cancer	2.37e-06	5.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	2.35e-06	5.85e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—pancreatic cancer	2.32e-06	5.79e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOE—pancreatic cancer	2.31e-06	5.76e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—pancreatic cancer	2.31e-06	5.76e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—pancreatic cancer	2.31e-06	5.76e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—pancreatic cancer	2.3e-06	5.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—pancreatic cancer	2.3e-06	5.74e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—pancreatic cancer	2.29e-06	5.7e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.27e-06	5.66e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CD44—pancreatic cancer	2.26e-06	5.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	2.23e-06	5.56e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—pancreatic cancer	2.19e-06	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOE—pancreatic cancer	2.18e-06	5.43e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	2.17e-06	5.4e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GCG—pancreatic cancer	2.16e-06	5.4e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOE—pancreatic cancer	2.16e-06	5.38e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—pancreatic cancer	2.15e-06	5.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—pancreatic cancer	2.13e-06	5.32e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SRC—pancreatic cancer	2.12e-06	5.29e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	2.12e-06	5.28e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	2.1e-06	5.25e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—pancreatic cancer	2.1e-06	5.23e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.08e-06	5.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	2.06e-06	5.15e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—pancreatic cancer	2.04e-06	5.1e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.04e-06	5.1e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRAS—pancreatic cancer	2.04e-06	5.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—pancreatic cancer	2.04e-06	5.08e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—STK11—pancreatic cancer	2.03e-06	5.07e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—pancreatic cancer	2.01e-06	5.02e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.96e-06	4.9e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.95e-06	4.86e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—pancreatic cancer	1.9e-06	4.74e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.9e-06	4.73e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	1.9e-06	4.73e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—pancreatic cancer	1.88e-06	4.69e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.88e-06	4.69e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—pancreatic cancer	1.87e-06	4.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOE—pancreatic cancer	1.84e-06	4.6e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	1.83e-06	4.57e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.83e-06	4.57e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.83e-06	4.56e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—pancreatic cancer	1.82e-06	4.53e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	1.78e-06	4.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—pancreatic cancer	1.76e-06	4.38e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.75e-06	4.36e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.75e-06	4.35e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.73e-06	4.31e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.71e-06	4.27e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.66e-06	4.15e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	1.64e-06	4.08e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	1.61e-06	4.02e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.61e-06	4.01e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.6e-06	3.98e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—pancreatic cancer	1.58e-06	3.95e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.58e-06	3.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—pancreatic cancer	1.56e-06	3.89e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.5e-06	3.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—pancreatic cancer	1.49e-06	3.72e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.49e-06	3.72e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.49e-06	3.72e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.48e-06	3.69e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.46e-06	3.65e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.46e-06	3.64e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOE—pancreatic cancer	1.42e-06	3.55e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—pancreatic cancer	1.38e-06	3.44e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—pancreatic cancer	1.34e-06	3.33e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	1.32e-06	3.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—pancreatic cancer	1.32e-06	3.29e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.3e-06	3.24e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.29e-06	3.22e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.29e-06	3.22e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.28e-06	3.2e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.27e-06	3.18e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.26e-06	3.15e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.24e-06	3.09e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.13e-06	2.82e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	1.12e-06	2.79e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.1e-06	2.75e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—pancreatic cancer	1.08e-06	2.69e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.05e-06	2.63e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	9.84e-07	2.45e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	9.75e-07	2.43e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	9.73e-07	2.43e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	9.17e-07	2.29e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—pancreatic cancer	9.13e-07	2.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	9.09e-07	2.27e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—pancreatic cancer	8.5e-07	2.12e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—pancreatic cancer	7.95e-07	1.98e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	7.77e-07	1.94e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—pancreatic cancer	7.49e-07	1.87e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—pancreatic cancer	7.43e-07	1.85e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—pancreatic cancer	6.35e-07	1.58e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	6e-07	1.5e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—pancreatic cancer	4.9e-07	1.22e-05	CbGpPWpGaD
